Next generation of Biosynthetic
CBD production

Company Overview

We focus on the development of an innovative, scalable and patentable biotechnological platform based on Synthetic Biology to produce commercially viable biosynthetic cannabidiol for the global pharmaceutical market. A Biosystem made to provide an easier, economical and reliable way to obtain large amounts of high-value compounds.

Cheaper

Purer

Faster

Current issues

Extraction & Genetic engineering

Extraction and purification of biomolecules from it's original source is complex and comes at high investment cost, slow cycles, no batch-to-batch consistency, toxic by-products and high carbon footprint.

On the other hand, genetically engineered microorganisms can be used as mini factories to produce the desired biomolecules.

However, certain biomolecules are more complicated to biosynthesize than others. Inneficient conversion from input biomass and metabolic burdens control productivity flow rates, making biomanufacturing low and unsufficient.

OUR SOLUTION

Cell-Free technology

Cell-free Technology is a state-of-the-art technique that allows us to reproduce cellular biological transformations. It works by generating a cascade of molecular reactions allowing us to create a diverse range of proteins and biomolecules from inexpensive substrates, in a controlled environment, outside of the constraints of the living cell.

x10

Titer

Faster

Cycles

99,9%

Purity

API

Compounds

First in our Pipeline

Cannabidiol (CBD)

CBD have shown medical and therapeutical applications for many diseases and conditions such as Epilepsy, Parkinson's, Arthritis, Inflammation, Pain and PTSD.

There are more than 119 cannabinoids identified, but most of them are difficult to obtain through extraction, making it hard to unravel new medical properties. (Left: CBD molecular structure).

In collaboration with:

Vision

“A world in which the collective consciousness has evolved by the use of technology to transcend and reach interconnectedness with the universe.”

Meet the Team

Federico Jara Crua

MSc Bioengineering - EPFL
Biologist - UdeC


» Co-founder

Rafael Alain Rolli

MSc Bioengineering - EPFL
BSc Life Sciences - EPFL


» Co-founder

Advisory Board

Prof. Sebastian Maerkl PhD

Laboratory of Biological Network
Characterization - EPFL


»  Science Advisor

Andres McAllister MD. PhD

Chief Medical Officer - BioInvent


» Business Advisor

WE WOULD LOVE TO GET IN TOUCH

Fields marked with an asterisk (*) are required.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.